patientlyw, I am not thinking 50/50 or 25/75 nor 75/25 chance of reverse split.
What I am thinking is that either PPHM has news that brings us above 1$ for 10 trading days (and CEO King thinks they may have such news) or they don't. With PPHM I calculate in that even in the even of such news the PPS might be played.
I even wonder if PPHM is still a US controlled company because the way the US allows trading/MM action/naked shorting etc these days it may well be that the nation wakes up some day realising that its crown jewels are owned by non-US entities that, under the greed of shorting and illegal naked sorting by others, grab the occasion to buy into companies that they believe have the goods.
PPHM is such company that without any doubt has the goods and of which the PPS is artificially low. So there is no big risk in keeping large amounts of shares as the company will yield the profits or get acquired anyways. And by the way, if that would not be the case I wouldn't be in this stock anymore since 2012. In Q3-Q4 2012 I got convinced (and now of course even more) that PPHM has the goods. AVid is a welcome bonus that will stop dilution, while I have no real problem with the dilution of the past because I think it is better then whatever 2B-5B$ PPHM could have wheeled in given the fact one kept its average price on level (which I have always done).
So 20$ per share now or then gives me the SAME leverage. Of course just like everyone I invest TIME to realise that leverage.
So a possible Reverse Split if we do not trade above 1$ before April 10 2017 (that is more then 120 days from now) will split the shares and increase the price. If PPHM has the news then they will be able to grow on that PPS. I think the PPS will in all cases be around 1$ and they might do a 1/7 to bring the stock in a price range where all brokers/II/Funds may buy it or advice it because it will be above 5$.
5$ would at that time be covered completely by:
- About 0.5Bil$ Tax advantages
- Avid Assets
- Avid 3rd party revenue
If the PPS is 5$ then the outstanding common shares are no longer 250Mil shares, so we stay about 250Mil$ Market Cap. The 3 items above are worth MORE then 250Mil$ as the tax advantage will probably be about 150Mil$ minimum tax deduction on 0.5B$ (I used 30% corporate tax-rate but not sure if that is correct for the US).
The PS-Targeting IP, the BetaBodies IP, the Exosome IP, the BioMarket IP, the related pipelines, the exosome PoC-Test (which should be ready by now or in Q1/2017), that PPHM all owns 100% unencumbered, the exosome partnering (100% intend), potential partnering deal(s) for Bavituximab, etc are not even counted in all that.
With the recent peer reviewed papers of Dr. Stopeck, Ceryl Empig, Dr. Bridge (Rutger's) and the presentations from the Dr. Brekken (+ex. Thorpe) Labs at Uni.Tex. SW and the Sloan Kettering memorial Lab's of Dr. Wolchok which all come down to Bavituximab's targeting PS resulting in a BETTER tumour environment (Mice and humans) and observed adaptive immune response (Mice and humans - see Stopeck's paper) there is NO DOUBT that the IP has big value for BP. The BP that get's it will knock the competition of their feet.
So for me the current PPS, the potential RS, etc is rather annoying through the delays it causes/caused but not more then that. This being said I think you remember I sympathise with all that are in this stock for many years and and are running out of time. I understand their opinions when they say they would take x$ now then x times y in 24-48 months.
While in the past the PPHM stock was qualified as LARGELY UNDERVALUED it was purely based on POTENTIAL. Today it is based on REAL VALUE/ASSETS (Labs), REAL measurable TAX deduction, measurable/growing and REPORTED 3rd party revenue (AVID) and a POTENTIAL of Bavituximab with WAY LESS RISK LEVELS then 2 or more years ago.
Market Data 
Markets 
AI
